VIVUS (VVUS) Higher as Qsymia Prescriptions Show Confident Growth
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Price: $0.47 --0%
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
VIVUS, Inc. (Nasdaq: VVUS) is up again Tuesday following new Qsymia sales data.
According to Source Healthcare Analytics, as cited by Bloomberg Industries, about 57 percent of Qsymia prescriptions were for the lowest dose, with 40 percent for the medium dose. Data shows that the low dose sells for $4.80 per day, while the higher dose goes for $5.42 per day.
Physicians prescribing Qsymia are recommended to issue the low dose for the first two weeks, escalating to the medium dose for the next 12 weeks, and then moving to a higher dosage or stopping treatment altogether.
Given that, it appears Qsymia prescriptions are moving along as planned and showing some robust growth.
VIVUS shares are up 1.4 percent in afternoon trading.
According to Source Healthcare Analytics, as cited by Bloomberg Industries, about 57 percent of Qsymia prescriptions were for the lowest dose, with 40 percent for the medium dose. Data shows that the low dose sells for $4.80 per day, while the higher dose goes for $5.42 per day.
Physicians prescribing Qsymia are recommended to issue the low dose for the first two weeks, escalating to the medium dose for the next 12 weeks, and then moving to a higher dosage or stopping treatment altogether.
Given that, it appears Qsymia prescriptions are moving along as planned and showing some robust growth.
VIVUS shares are up 1.4 percent in afternoon trading.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand
- Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
Create E-mail Alert Related Categories
Analyst Comments, FDA, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
